Andera Partners has filed an amended Schedule 13G, revealing an increase in its ownership stake in Inventiva S.A. to 6.7%. This move is significant as it reflects Andera's growing influence within the pharmaceutical sector, particularly in the management and strategic direction of Inventiva.

Andera Partners, a Paris-based investment firm, is known for its focus on life sciences, and this latest filing indicates its commitment to strengthening its position in the industry. The firm, along with BioDiscovery 6, holds a substantial number of shares, which could impact future decisions made by Inventiva.

Background

Andera Partners, with a CIK of 0001757283, is categorized under the entity type 'other'. The firm is based in Paris, France, and specializes in investments within the life sciences sector. Its recent filings include a Schedule 13G/A filed on October 27, 2026, and a 13F-HR filed on October 16, 2026.

What the Filing Says

The filing states that Andera Partners and its affiliates collectively own 15,929,476 ordinary shares of Inventiva S.A., accounting for 6.7% of the company. The filing notes, "Voting and dispositive decisions with respect to the securities held by BioDiscovery 6 are made by its management company, Andera." This indicates a strategic partnership between the two entities.

Impact

This increase in ownership may affect various stakeholders, including existing shareholders and the management team at Inventiva. With Andera's significant voting power, the firm could influence key decisions regarding the company's direction and strategy.

What's Next

The filing does not say what happens next.